Topics

EpimAb Biotherapeutics Company Profile

22:03 EDT 21st September 2019 | BioPortfolio

EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company based in Shanghai with a proprietary unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties. With this platform EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients. EpimAb is also committed to diversifying its pipeline through selective licensing of its platform to partners worldwide. For further information, please visit www.epimab.com


News Articles [264 Associated News Articles listed on BioPortfolio]

EpimAb Biotherapeutics is Granted US Patent on Core Bispecific Antibody Technology

Patent protects EpimAb’s core technology FIT-Ig® and its entire bispecific pipeline with a broad composition of matter claim EpimAb Biotherapeutics, an emerging biop...

Shanghai's EpimAb Completes $74 Million Series B for Bi-Specific Antibodies

EpimAb Biotherapeutics, a Shanghai bi-specifics company focused on cancer and immunotherapies, closed a $74 million Series B financing. The company uses its FIT-Ig® (Fabs-In-Tandem Immunoglobulin)...

China's EpimAb Biotherapeutics Raises $74 Million in Series B to Advance Solid Tumor Therapy

EpimAb plans to use the funds to advance its Phase I/II clinical program, EMB01, expand its clinical pipeline into immuno-oncology and other areas and add a new manufacturing site in Suzhou for proces...

Series B round brings in $74mm for EpimAb

EpimAb Biotherapeutics Inc. (bispecific antibodies for cancer) raised $74mm through its Series B round co-led by new board members SDIC Fund and Sherpa Healthcare Partners. Also participating were SCV...

@EpimAb_Bio EpimAb Biotherapeutics

Our CBO, Stephan Lensky, is presenting at the 26th @BioCentury #NewsMakers in #NYC on September 6. Stop by and reach out if you’re interested in a meeting! http://bit.ly

EpimAb Biotherapeutics Raises $74M in Series B Financing

Funding to be used in growing and advancing the Company’s clinical pipeline of novel bispecific antibodies EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutic...

EpimAb raises $74M series B round to accelerate bispecific immuno-oncology pipeline expansion

How EpimAb plans to use its $74M series B to accelerate its bispecific pipeline of immuno-oncology candidates.

China's EpimAb Advances Bispecific Antibody To Rival Janssen Candidate

EpimAb's business development officer tells Scrip dosing has started in a Phase I/II trial assessing the China-based biotech's lead cancer molecule...  

Drugs and Medications [6 Associated Drugs and Medications listed on BioPortfolio]

Hepagam b [aptevo biotherapeutics llc]

These highlights do not include all the information needed to use HepaGam B safely and effectively. See full prescribing information for HepaGam B. HepaGam B [Hepatitis B Immune Globulin Intravenous (...

Hepagam b [aptevo biotherapeutics llc]

These highlights do not include all the information needed to use HepaGam B safely and effectively. See full prescribing information for HepaGam B. HepaGam B [Hepatitis B Immune Globulin Intravenous (...

Atryn [gtc biotherapeutics, inc.]

These highlights do not include all the information needed to use ATryn safely and effectively. See full prescribing information for ATryn. ATryn, Antithrombin (Recombinant) Lyophilized powder for rec...

Winrho [aptevo biotherapeutics llc]

These highlights do not include all the information needed to use WinRho SDF safely and effectively. See full prescribing information for WinRho SDF. WinRho SDF [Rho(D) Immune Globulin Intravenous (Hu...

Ixinity [aptevo biotherapeutics llc]

These highlights do not include all the information needed to use IXINITY® safely and effectively. See full prescribing information for IXINITY.. IXINITY [coagulation factor IX (recombinant)] Lyophil...

PubMed Articles [19 Associated PubMed Articles listed on BioPortfolio]

Characterization and prediction of positional 4-hydroxyproline and sulfotyrosine, two post-translational modifications that can occur at substantial levels in CHO cells-expressed biotherapeutics.

Biotherapeutics may contain a multitude of different post-translational modifications (PTMs) that need to be assessed and possibly monitored and controlled to ensure reproducible product quality. Duri...

Reliable LC-MS Multi-Attribute Method for Biotherapeutics by Run-Time Response Calibration.

A major challenge of a mass spectrometry-based quantitative multi-attribute method (MAM) for biotherapeutics is its high variability between instruments. For reproducible attribute measurements, not o...

Development and validation of a multiplexed drug level assay in support of combination biologics therapy clinical studies.

Clinical development of biotherapeutics for combination therapy requires monitoring the concentrations of both drugs in biological samples. Traditionally, two assays are required to measure drug level...

TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity.

Most immune responses to biotherapeutic proteins involve the development of anti-drug antibodies (ADAs). New drugs must undergo immunogenicity assessments to identify potential risks at early stages i...

Chemoenzymatic synthesis of glycoproteins.

The majority of the world's best-selling biotherapeutics are glycoproteins. However their production using cellular expression systems invariably produces inseparable mixtures of materials which diffe...

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

The purpose of this study is to: - evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) a...

A Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study

This is a Phase 2, randomized, double-blind, placebo-controlled crossover study which will enroll up to 36 subjects (anticipated) with genetically confirmed mitochondrial disease who have ...

The Effect of OASIS Ultra on Critical Sized Wound Healing

The aim of this study is to evaluate the speed and quality with which OASIS® Ultra (Healthpoint Biotherapeutics; Fort Worth, Texas) increases wound healing in the critical sized defect. ...

Personalized Immunotherapeutics for Antibiotic-resistant Infection

M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...

ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients

Finding a donor remains a challenge for patients in need of an urgent hematopoietic stem cell transplantation (HSCT). The ability to obtain half matched stem cells from any family member r...

Companies [111 Associated Companies listed on BioPortfolio]

EpimAb Biotherapeutics EpimAb Biotherapeutics

EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D company based in Shanghai with a proprietary and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunogl...

EpimAb Biotherapeutics

EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company based in Shanghai with a proprietary unique and efficient technology called FIT-Ig® (Fabs-In-Tandem...

EpimAb

Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics ...

Napro Biotherapeutics Incorporated

NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent ...

More Information about "EpimAb Biotherapeutics" on BioPortfolio

We have published hundreds of EpimAb Biotherapeutics news stories on BioPortfolio along with dozens of EpimAb Biotherapeutics Clinical Trials and PubMed Articles about EpimAb Biotherapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of EpimAb Biotherapeutics Companies in our database. You can also find out about relevant EpimAb Biotherapeutics Drugs and Medications on this site too.

Quick Search

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...


Corporate Database Quicklinks



Searches Linking to this Company Record